11
Views
2
CrossRef citations to date
0
Altmetric
Research Article

Production of Serum-free and Total Prostate-specific Antigen Due to Prostatic Intraepithelial Neoplasia

, , , , &
Pages 323-329 | Published online: 09 Jul 2009

  • Bostwick DG, Brawer MK. Prostatic intraepithelial neoplasia and early invasion in prostate cancer. Cancer 1987; 59: 788-94.
  • Bostwick DG. Prostatic intraepithelial neoplasia, the most likely precursor of prostate cancer. Cancer 1995; 75: 1823-6.
  • Bostwick DG, Montironi R. Evaluating radical prostatectomy specimens: therapeutic and prognostic importance. Virchows Arch 1997; 430: 1-16.
  • Bostwick DG, Qian J, Frankel K. Incidence of HGPIN in needle biopsies. J Urol 1995; 154: 1791-4.
  • Pacelli A, Bostwick DG. Clinical significance of high grade prostatic intraepithelial neoplasia in transurethral resection specimens. Urology 1997; 50: 355-9.
  • Keetch DW, Humphrey P, Stahl D, Smith DS, Catalona WJ. Morphometric analysis and clinical followup of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 1995; 154: 347-51.
  • Weinstein MH, Epstein JI. Significance of high-grade prostatic intraepithelial neoplasia on needle biopsy. Hum Pathol 1993; 24: 624-9.
  • Shepherd D, Keetch DW, Humphrey PA, Smith DS, Stahl D. Repeated biopsy strategy in men with isolated prostatic intraepithelial neoplasia on prostate needle biopsy. J Urol 1996; 156: 460-2.
  • Haggman MJ, Adolfsson J, Khoury S, Montie JE, Norlen J. Clinical management of premalignant lesions of the prostate. WHO collaborative project and consensus conference on public health and clinical significance of premalignant alterations in the genitourinary tract. Scand J Urol Nephrol Suppl 2000; 205: 44-9.
  • Zlotta AR, Schulman CC. Clinical evolution of prostatic intraepithelial neoplasia. Eur Urol 1999; 35: 498-503.
  • Chan TY, Epstein JI. Follow-up of atypical prostate needle biopsies suspicious for cancer. Urology 1999; 53: 351-5.
  • Basso D, Fogar P, Piva MG, Navaglia F, Mazza S, Prayer-Galetti T, et al. Total PSA, free PSA/total PSA ratio, and molecular PSA detection in prostate cancer: which is clinically effective and when? Urology 2000; 55: 710-5.
  • Davidson D, Siroky M, Rudders R, Qian J, Oesterling J, Bostwick DG, et al. Prostatic intraepithelial neoplasia is predictive of adenocarcinoma: retrospective study of 100 cases. Mod Pathol 1996; 7: 74A.
  • Raviv G, Zlotta AR, Jansenn Th, Descamps F, Venegas JP, Verliest A, et al. Do PSA and PSAD enhance the detection of prostate carcinoma after initial diagnosis of prostatic intraepithelial neoplasia without concurrent carcinoma? Cancer 1996; 77: 2103-8.
  • Montironi R. Antigene prostatico specifico sierico nella neoplasia prostatica intraepiteliale. In: Rigatti P, Scattoni V, eds. PSA, antigene prostatico specifico. Pavia, Italy: Edimes, 1997: 117-27.
  • Alexander EE, Qian J, Wollan PC, Myers RP, Bostwick DG. Prostatic intraepithelial neoplasia does not appear to raise serum prostatic-specific antigen concentration. Urology 1996; 47: 693-8.
  • Ronnette BM, Carmichael MJ, Carter BH, Epstein JI. Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol 1993; 150: 386-9.
  • Jung K, Elgeti U, Lein M, Brux B, Sinha P, Rudolph B, et al. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? Clin Chem 2000; 46: 55-62.
  • Polito M, Muzzonigro G, Hanitzsch H, Galosi AB, Polito Jr M, Minardi D, et al. Ruolo della Neoplasia Prostatica Intraepiteliale (PIN) nella produzione di PSA sierico totale e libero. Acta Urol Ital 1998; 12 (Suppl): 260-1.
  • Mazzucchelli R, Colanzi P, Pomante R, Muzzonigro G, Montiron R. Prostate tissue and serum markers. Adv Clin Pathol 2000; 4: 111-20.
  • Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson P, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090-5.
  • Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW. Analysis of percent free prostate specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 1996; 48 (Suppl): 55-61.
  • Minardi D, Galosi AB, Recchioni A, Giammarco L, Polito M, Muzzonigro G. Diagnostic accuracy of percent free PSA in prostatic pathology and its usefulness in monitoring prostatic cancer patients. Urol Int 2001; 67: 272-82.
  • Marley GM, Miller MC, Smith J, O'Dowd GJ, Veltri RW. Free/total prostate specific antigen serum ratios distinguish high-grade prostatic intraepithelial neoplasia from prostate cancer. J Urol 1997; 157 (Suppl): 232A.
  • Kilic S, Kabul E, Danisman A, Güntekin E, Sevük M. Ratio of free to total prostate-specific antigen in patients with prostatic intraepithelial neoplasia. Eur Urol 1998; 34: 176-80.
  • Tarle M, Kraljic I. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer? Anticancer Res 1997; 17(3A): 1531-4.
  • Tarle M, Kraljic I. Serum free/total percent PSA value as a clinical tool for discriminating latent from manifest prostatic carcinoma. Acta Clin Crot 1997; 36: 15-9.
  • Ramos CG, Carvahal GF, Mager DE, Haberer B, Catalona WJ. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. J Urol 1999; 162: 1587-90.
  • Stephan C, Lein M, Jung K, Schnorr D, Loening SA. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1991; 79: 756-9.
  • Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Prostatic volume and ratio free-to-total prostate specific antigen with prostatic cancer or benign prostatic hyperplasia. J Urol 1997; 158: 2188-92.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.